RNA vs AVTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 11, 2026

RNA

48.7
AI Score
VS
RNA Wins

AVTX

42.3
AI Score

Investment Advisor Scores

RNA

49score
Recommendation
HOLD

AVTX

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA AVTX Winner
Net Income -36.82M -64.54M RNA
Operating Income -39.90M -53.18M RNA
ROE -17.2% -70.5% RNA
ROA -13.1% -51.6% RNA
Total Assets 280.51M 125.10M RNA
Cash 72.33M 26.96M RNA
Current Ratio 8.73 14.28 AVTX

Relative Price Performance (Last 90 Days)

RNA 1M: -14.9% · 3M: -16.7% AVTX 1M: -17.5% · 3M: +17.9%

Current Technical Phase

RNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 31

RSI (14): 31.2 · Price: $10.36

AVTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 33

RSI (14): 32.6 · Price: $16.12

Fundamentals Snapshot

Metric RNA AVTX
Market Cap
Forward P/E -1.3 -5.9
Trailing P/E
Revenue (TTM)
Revenue Growth -0.2% -0.7%
Gross Margin -0.6% -811.7%
Operating Margin -7.5% -1548.5%
EPS -5.36 -4.16
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.